Accelerated Onset of Liver Failure after Prolonged Adjuvant Tamoxifen Use in Breast Cancer Patients

Download Citation in txt Download Citation in bib Download Citation in ris

Author Info

Hayley M. Heers Lida Mina Shakeela W Bahadur Shannon Lim

Corresponding Author

Hayley M. Heers
PGY2 Oncology Pharmacy Resident, Banner MD Anderson Cancer Center, Arizona, USA

A B S T R A C T

Use of adjuvant endocrine therapy for women with hormone-receptor (HR)-positive breast cancer has become the standard of care. Tamoxifen, an orally available selective estrogen receptor modulator (SERM), is a commonly used endocrine therapy agent currently recommended for use in pre- or post-menopausal women with HR-positive breast cancer. Current evidence suggests that prolonged tamoxifen use may be implicated in causing hepatotoxicity which may manifest as non-alcoholic steatohepatitis (NASH), cholestasis, cirrhosis, or hepatic necrosis. We herein present two cases of suspected tamoxifen-induced NASH resulting in fulminant liver failure. We also discuss literature surrounding tamoxifen-related hepatoxicity and implications in clinical practice.

Article Info

Article Type

Case Report

Publication history

Received: Sat 11, Apr 2020
Accepted: Mon 27, Apr 2020
Published: Wed 29, Apr 2020

Copyright

© 2023 Hayley M. Heers. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2020.04.11